Compare HOUR & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOUR | MDXH |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.3M | 68.7M |
| IPO Year | 2021 | 2021 |
| Metric | HOUR | MDXH |
|---|---|---|
| Price | $1.88 | $0.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 8.2K | ★ 15.5M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 150.00 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $142,440,236.00 | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | $37.30 | ★ N/A |
| Revenue Growth | ★ 3.03 | N/A |
| 52 Week Low | $1.67 | $0.40 |
| 52 Week High | $6.84 | $5.33 |
| Indicator | HOUR | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 50.89 | 58.35 |
| Support Level | $1.74 | $0.68 |
| Resistance Level | $2.04 | $1.13 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 63.16 | 12.12 |
Hour Loop Inc is a technology-enabled consumer products company that uses machine learning and data analytics to design, develop, market, and sell products. Hour Loop predominantly operates through online retail channels such as Amazon, Walmart, and Hourloop.com. The company, as an Internet marketplace seller, sells products in multiple categories, including home/garden decor, toys, kitchenware, apparel, and electronics. It has only one segment, which is online retail (e-commerce).
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.